The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490 · cited 1×
“Recent diagnostic studies underscore the interplay of EGFR, HER3, and their ligands in HNSCC (Hickinson et al., 2009).”
BackgroundStructural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Self-citationA quantitative protein interaction network for the ErbB receptors using protein microarrays
Jones, R. B., Gordus, A., Krall, J. A., & MacBeath, G. (2006) · Nature · doi:10.1038/nature04177 · Cited by 727
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., & Carraway, K. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36676-0 · Cited by 643
Self-citationMechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
Jura, N., Endres, N. F., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009) · Cell · doi:10.1016/j.cell.2009.04.025 · Cited by 606
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
Wheeler, D. L., Huang, S., Kruser, T. J., Nechrebecki, M. M., Armstrong, E. A., Benavente, S., Gondi, V, Hsu, K.-T., & Harari, P. M. (2008) · Oncogene · doi:10.1038/onc.2008.19 · Cited by 550
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497
Engelman, J. A., Jänne, P. A., Mermel, C., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 493
Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether
Cho, H.-S., & Leahy, D. J. (2002) · Science · doi:10.1126/science.1074611 · Cited by 447
Gessner, J. E., Heiken, H., Tamm, A., & Schmidt, R. E. (1998) · Annals of Hematology · doi:10.1007/s002770050396 · Cited by 404
Zhou, B.-B. S., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y., Baribaud, F., Mikami, I., Reguart, N., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.024 · Cited by 374
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Bostrom, J., Yu, S.-F., Kan, D., Appleton, B. A., Lee, C. V., Billeci, K., Man, W., Peale, F., Ross, S., Wiesmann, C., et al. (2009) · Science · doi:10.1126/science.1165480 · Cited by 370
Self-citationThe erbB3 gene product is a receptor for heregulin.
Carraway, K. L., Sliwkowski, M. X., Akita, R., Platko, J. V., Guy, P. M., Nuijens, A., Diamonti, A. J., Vandlen, R. L., Cantley, L. C., & Cerione, R. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36789-3 · Cited by 362
Self-citationSchoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B., Kalra, A., Paragas, V., Bukhalid, R., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000352 · Cited by 360
Prigent, S. A., & Gullick, W. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06577.x · Cited by 359
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Jura, N., Shan, Y., Cao, X., Shaw, D. E., & Kuriyan, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912101106 · Cited by 338
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Engelman, J. A., & Settleman, J. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 284
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation
Schoeberl, B., Faber, A. C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3145 · Cited by 264
Skin toxicities associated with epidermal growth factor receptor inhibitors
Li, T., & Perez-Soler, R. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0114-0 · Cited by 261
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Presta, L. G. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.026 · Cited by 246
Lee, C. V., Liang, W.-C., Dennis, M. S., Eigenbrot, C., Sidhu, S. S., & Fuh, G. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.05.051 · Cited by 227
Self-citationSchneider-Merck, T., Lammerts van Bueren, J. J., Berger, S., Rossen, K., van Berkel, P. H. C., Derer, S., Beyer, T., Lohse, S., Bleeker, W. K., Peipp, M., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900847 · Cited by 222
Junttila, T. T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, L., Pabonan, O., Baginski, T., Meng, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3704 · Cited by 221
Self-citationErbB3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor
Soltoff, T. P., Carraway, K. L., Prigent, S. A., Gullick, W. G., & Cantley, L. C. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3550-3558.1994 · Cited by 205
Targeting the function of the HER2 oncogene in human cancer therapeutics
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210478 · Cited by 190
Campbell, M. R., Amin, D., & Moasser, M. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1218 · Cited by 188
Lutterbuese, R., Raum, T., Kischel, R., Hoffmann, P., Mangold, S., Rattel, B., Friedrich, M., Thomas, O., Lorenczewski, G., Rau, D., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000976107 · Cited by 166
Bleeker, W. K., van Bueren, J. J. L., van Ojik, H. H., Gerritsen, A. F., Pluyter, M., Houtkamp, M., Halk, E., Goldstein, J., Schuurman, J., van Dijk, M. A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.7.4699 · Cited by 152
Buck, E. A., Eyzaguirre, A., Haley, J. D., Gibson, N. W., Cagnoni, P. J., & Iwata, K. K. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0007 · Cited by 133
Lynch, D. H., & Yang, X. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31522 · Cited by 128
Tabernero, J., Cervantes, A., Rivera, F., Martinelli, E., Rojo, F., von Heydebreck, A., Macarulla, T., Rodriguez-Braun, E., Eugenia Vega-Villegas, M., Senger, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6043 · Cited by 110 · cited 1×
“These data are in agreement with clinical observations of strong downmodulation of MAPK signaling but not AKT signaling in skin and tumor biopsies of patients treated with anti-EGFR agents (Folprecht et al., 2008; Tabernero et al., 2010).”
ResultSchaefer, G., Fitzpatrick, V. D., & Sliwkowski, M. X. (1997) · Oncogene · doi:10.1038/sj.onc.1201317 · Cited by 104
Self-citationTaylor, R. J., Chan, S., Wood, A., Voskens, C., Wolf, J. S., Lin, W., Chapoval, A. I., Schulze, D. H., Tian, G., & Strome, S. E. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0613-3 · Cited by 103
Robak, T. (2009) · PubMed · Cited by 87
Schaefer, G., Shao, L., Tótpál, K., & Akita, R. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3493 · Cited by 87
Self-citationThe Role of Gefitinib in Lung Cancer Treatment
Giaccone, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040005 · Cited by 82
Kong, A. H., Calleja, V., Leboucher, P., Harris, A. L., Parker, P. J., & Larijani, B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002881 · Cited by 74
Jain, A., Penuel, E. M., Mink, S. R., Schmidt, J., Hodge, A., Favero, K., Tindell, C., & Agus, D. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3326 · Cited by 68
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells
Lee, C. V., Hymowitz, S. G., Wallweber, H. J. A., et al. (2006) · Blood · doi:10.1182/blood-2006-03-011031 · Cited by 67
Self-citationEGFR Antibodies in Colorectal Cancer: Where Do They Belong?
Grothey, A. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.3407 · Cited by 47
Folprecht, G., Tabernero, J. M., Köhne, C., Zacharchuk, C., Paz-Ares, L. G., Rojo, F., Quinn, S., Casado, E., Salazar, R., Abbas, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1053 · Cited by 26
Hickinson, D. M., Marshall, G. B., Beran, G. J., Varella‐Garcia, M., Mills, E. A., South, M. C., Cassidy, A. M., Acheson, K., McWalter, G., McCormack, R., et al. (2009) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2009.00099.x · Cited by 23
Cited by
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
“The first evidence for a role of ERBB2 or HER2 (for human EGFR2) in cancer was inferred from the connection to its rat ortholog, Neu, amutant cDNA isolated from carcinogen-induced neuroblastomas (Schechter et al., 1984).”
BackgroundThe ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3309 · Cited by 988
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Metadata
- Authors
- Schaefer, G., Haber, L., Crocker, L. M., Shia, S., Shao, L., Dowbenko, D., Totpal, K., Wong, A., Lee, C. V., Stawicki, S., Clark, R., Fields, C., Lewis Phillips, G. D., Prell, R. A., Danilenko, D. M., Franke, Y., Stephan, J.-P., Hwang, J., Wu, Y., Bostrom, J., Sliwkowski, M. X., Fuh, G., & Eigenbrot, C.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 20
- Issue
- 4
- Pages
- 472-486
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2085690948
- Cited by
- 341
- References
- 51
- FWCI
- 15.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.